Levetiracetam-induced transaminitis in a young male with traumatic brain injury

Abstract Levetiracetam is a commonly prescribed antiepileptic drug for seizure prophylaxis in patients with traumatic brain injury (TBI). Levetiracetam metabolism has been reported to be non-dependent on hepatic cytochrome P450 (CYP450) isoenzyme system. Furthermore, levetiracetam and its metabolite...

Full description

Saved in:
Bibliographic Details
Published in:Oxford Medical Case Reports 2017-11, Vol.2017 (11), p.omx067
Main Authors: Rachamallu, Vivekananda, Song, Michael M, Reed, Jace M, Aligeti, Manish
Format: Article
Language:English
Subjects:
Case Report
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c405t-c42d41388d5b1b2cd3186f1bacba23d4f30f64e40dc30d7246e8391bdb1785d3
cites cdi_FETCH-LOGICAL-c405t-c42d41388d5b1b2cd3186f1bacba23d4f30f64e40dc30d7246e8391bdb1785d3
container_end_page
container_issue 11
container_start_page omx067
container_title Oxford Medical Case Reports
container_volume 2017
creator Rachamallu, Vivekananda
Song, Michael M
Reed, Jace M
Aligeti, Manish
description Abstract Levetiracetam is a commonly prescribed antiepileptic drug for seizure prophylaxis in patients with traumatic brain injury (TBI). Levetiracetam metabolism has been reported to be non-dependent on hepatic cytochrome P450 (CYP450) isoenzyme system. Furthermore, levetiracetam and its metabolites are reported to be eliminated from systemic circulation via renal excretion. Therefore, due to its well-known renal clearance mechanism with no dosage adjustments recommended for hepatic impairment, levetiracetam is often chosen as the drug of choice in patients with suspected or ongoing hepatic dysfunction. Furthermore, monitoring of liver enzymes is often not considered to be critical in levetiracetam therapy. However, hepatotoxicity is still possible with levetiracetam. Here, we report on an 18-year-old male with TBI who developed transaminitis with levetiracetam therapy which resolved following the discontinuation of levetiracetam. A close monitoring of liver enzymes and early recognition of hepatotoxicity is still necessary and critical to preventing major sequelae stemming from levetiracetam-induced hepatotoxicity.
doi_str_mv 10.1093/omcr/omx067
format article
fullrecord <record><control><sourceid>oup_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5934633</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/omcr/omx067</oup_id><sourcerecordid>10.1093/omcr/omx067</sourcerecordid><originalsourceid>FETCH-LOGICAL-c405t-c42d41388d5b1b2cd3186f1bacba23d4f30f64e40dc30d7246e8391bdb1785d3</originalsourceid><addsrcrecordid>eNp9kL1rwzAQxUVpaUKaqXvx1KW4lSzJlpdCCekHBLJkF_pyohDJQbLT5r-vjduQLl3uDu537x4PgFsEHxEs8VPtVOjKF8yLCzDOIMUpY5Rens0jMI1xCyFEOEeYsWswysqCEITKMVguzME0NghlGuFS63WrjE6aIHwUznrb2JhYn4jkWLd-nTixM8mnbTY90jrRWJXIIDrC-m0bjjfgqhK7aKY_fQJWr_PV7D1dLN8-Zi-LVBFIm65mmvRmNJVIZkpjxPIKSaGkyLAmFYZVTgyBWmGoi4zkhuESSS1RwajGE_A8yO5b6YxWxnd2dnwfrBPhyGth-d-Ntxu-rg-clpjkGHcCD4OACnWMwVSnWwR5nyzvk-VDsh19d_7uxP7m2AH3A1C3-3-VvgE38IWX</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Levetiracetam-induced transaminitis in a young male with traumatic brain injury</title><source>Oxford Journals Online</source><source>PubMed Central</source><creator>Rachamallu, Vivekananda ; Song, Michael M ; Reed, Jace M ; Aligeti, Manish</creator><creatorcontrib>Rachamallu, Vivekananda ; Song, Michael M ; Reed, Jace M ; Aligeti, Manish</creatorcontrib><description>Abstract Levetiracetam is a commonly prescribed antiepileptic drug for seizure prophylaxis in patients with traumatic brain injury (TBI). Levetiracetam metabolism has been reported to be non-dependent on hepatic cytochrome P450 (CYP450) isoenzyme system. Furthermore, levetiracetam and its metabolites are reported to be eliminated from systemic circulation via renal excretion. Therefore, due to its well-known renal clearance mechanism with no dosage adjustments recommended for hepatic impairment, levetiracetam is often chosen as the drug of choice in patients with suspected or ongoing hepatic dysfunction. Furthermore, monitoring of liver enzymes is often not considered to be critical in levetiracetam therapy. However, hepatotoxicity is still possible with levetiracetam. Here, we report on an 18-year-old male with TBI who developed transaminitis with levetiracetam therapy which resolved following the discontinuation of levetiracetam. A close monitoring of liver enzymes and early recognition of hepatotoxicity is still necessary and critical to preventing major sequelae stemming from levetiracetam-induced hepatotoxicity.</description><identifier>ISSN: 2053-8855</identifier><identifier>EISSN: 2053-8855</identifier><identifier>DOI: 10.1093/omcr/omx067</identifier><identifier>PMID: 29744119</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Case Report</subject><ispartof>Oxford Medical Case Reports, 2017-11, Vol.2017 (11), p.omx067</ispartof><rights>The Author 2017. Published by Oxford University Press. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c405t-c42d41388d5b1b2cd3186f1bacba23d4f30f64e40dc30d7246e8391bdb1785d3</citedby><cites>FETCH-LOGICAL-c405t-c42d41388d5b1b2cd3186f1bacba23d4f30f64e40dc30d7246e8391bdb1785d3</cites><orcidid>0000-0002-4198-0119</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934633/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934633/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,733,786,790,891,1591,27957,27958,53827,53829</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29744119$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rachamallu, Vivekananda</creatorcontrib><creatorcontrib>Song, Michael M</creatorcontrib><creatorcontrib>Reed, Jace M</creatorcontrib><creatorcontrib>Aligeti, Manish</creatorcontrib><title>Levetiracetam-induced transaminitis in a young male with traumatic brain injury</title><title>Oxford Medical Case Reports</title><addtitle>Oxf Med Case Reports</addtitle><description>Abstract Levetiracetam is a commonly prescribed antiepileptic drug for seizure prophylaxis in patients with traumatic brain injury (TBI). Levetiracetam metabolism has been reported to be non-dependent on hepatic cytochrome P450 (CYP450) isoenzyme system. Furthermore, levetiracetam and its metabolites are reported to be eliminated from systemic circulation via renal excretion. Therefore, due to its well-known renal clearance mechanism with no dosage adjustments recommended for hepatic impairment, levetiracetam is often chosen as the drug of choice in patients with suspected or ongoing hepatic dysfunction. Furthermore, monitoring of liver enzymes is often not considered to be critical in levetiracetam therapy. However, hepatotoxicity is still possible with levetiracetam. Here, we report on an 18-year-old male with TBI who developed transaminitis with levetiracetam therapy which resolved following the discontinuation of levetiracetam. A close monitoring of liver enzymes and early recognition of hepatotoxicity is still necessary and critical to preventing major sequelae stemming from levetiracetam-induced hepatotoxicity.</description><subject>Case Report</subject><issn>2053-8855</issn><issn>2053-8855</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kL1rwzAQxUVpaUKaqXvx1KW4lSzJlpdCCekHBLJkF_pyohDJQbLT5r-vjduQLl3uDu537x4PgFsEHxEs8VPtVOjKF8yLCzDOIMUpY5Rens0jMI1xCyFEOEeYsWswysqCEITKMVguzME0NghlGuFS63WrjE6aIHwUznrb2JhYn4jkWLd-nTixM8mnbTY90jrRWJXIIDrC-m0bjjfgqhK7aKY_fQJWr_PV7D1dLN8-Zi-LVBFIm65mmvRmNJVIZkpjxPIKSaGkyLAmFYZVTgyBWmGoi4zkhuESSS1RwajGE_A8yO5b6YxWxnd2dnwfrBPhyGth-d-Ntxu-rg-clpjkGHcCD4OACnWMwVSnWwR5nyzvk-VDsh19d_7uxP7m2AH3A1C3-3-VvgE38IWX</recordid><startdate>20171101</startdate><enddate>20171101</enddate><creator>Rachamallu, Vivekananda</creator><creator>Song, Michael M</creator><creator>Reed, Jace M</creator><creator>Aligeti, Manish</creator><general>Oxford University Press</general><scope>TOX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4198-0119</orcidid></search><sort><creationdate>20171101</creationdate><title>Levetiracetam-induced transaminitis in a young male with traumatic brain injury</title><author>Rachamallu, Vivekananda ; Song, Michael M ; Reed, Jace M ; Aligeti, Manish</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c405t-c42d41388d5b1b2cd3186f1bacba23d4f30f64e40dc30d7246e8391bdb1785d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Case Report</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rachamallu, Vivekananda</creatorcontrib><creatorcontrib>Song, Michael M</creatorcontrib><creatorcontrib>Reed, Jace M</creatorcontrib><creatorcontrib>Aligeti, Manish</creatorcontrib><collection>Open Access: Oxford University Press Open Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oxford Medical Case Reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rachamallu, Vivekananda</au><au>Song, Michael M</au><au>Reed, Jace M</au><au>Aligeti, Manish</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Levetiracetam-induced transaminitis in a young male with traumatic brain injury</atitle><jtitle>Oxford Medical Case Reports</jtitle><addtitle>Oxf Med Case Reports</addtitle><date>2017-11-01</date><risdate>2017</risdate><volume>2017</volume><issue>11</issue><spage>omx067</spage><pages>omx067-</pages><issn>2053-8855</issn><eissn>2053-8855</eissn><abstract>Abstract Levetiracetam is a commonly prescribed antiepileptic drug for seizure prophylaxis in patients with traumatic brain injury (TBI). Levetiracetam metabolism has been reported to be non-dependent on hepatic cytochrome P450 (CYP450) isoenzyme system. Furthermore, levetiracetam and its metabolites are reported to be eliminated from systemic circulation via renal excretion. Therefore, due to its well-known renal clearance mechanism with no dosage adjustments recommended for hepatic impairment, levetiracetam is often chosen as the drug of choice in patients with suspected or ongoing hepatic dysfunction. Furthermore, monitoring of liver enzymes is often not considered to be critical in levetiracetam therapy. However, hepatotoxicity is still possible with levetiracetam. Here, we report on an 18-year-old male with TBI who developed transaminitis with levetiracetam therapy which resolved following the discontinuation of levetiracetam. A close monitoring of liver enzymes and early recognition of hepatotoxicity is still necessary and critical to preventing major sequelae stemming from levetiracetam-induced hepatotoxicity.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>29744119</pmid><doi>10.1093/omcr/omx067</doi><orcidid>https://orcid.org/0000-0002-4198-0119</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2053-8855
ispartof Oxford Medical Case Reports, 2017-11, Vol.2017 (11), p.omx067
issn 2053-8855
2053-8855
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5934633
source Oxford Journals Online; PubMed Central
subjects Case Report
title Levetiracetam-induced transaminitis in a young male with traumatic brain injury
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T22%3A56%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Levetiracetam-induced%20transaminitis%20in%20a%20young%20male%20with%20traumatic%20brain%20injury&rft.jtitle=Oxford%20Medical%20Case%20Reports&rft.au=Rachamallu,%20Vivekananda&rft.date=2017-11-01&rft.volume=2017&rft.issue=11&rft.spage=omx067&rft.pages=omx067-&rft.issn=2053-8855&rft.eissn=2053-8855&rft_id=info:doi/10.1093/omcr/omx067&rft_dat=%3Coup_pubme%3E10.1093/omcr/omx067%3C/oup_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c405t-c42d41388d5b1b2cd3186f1bacba23d4f30f64e40dc30d7246e8391bdb1785d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/29744119&rft_oup_id=10.1093/omcr/omx067&rfr_iscdi=true